Table 2.
Clinical features of participants.
| Variablea | Control (18) | PCOS (20) | p-valuec |
|---|---|---|---|
| Age (years) | 32.72 ± 1.10 | 31.71 ± 0.65 | > 0.05 |
| AMH (ng/ml) | 3.48 ± 1.095 | 11.07 ± 3 | < 0.05 |
| BMI (kg/m2) | 24.13 ± 0.85 | 26.58 ± 0.56 | > 0.05 |
| FBS (mg/dl) | 99.11 ± 3.98 | 92.23 ± 3.54 | > 0.05 |
| FSH (mUI/ml) | 5.25 ± 0.70 | 5.32 ± 0.6 | > 0.05 |
| LH (mUI/ml) | 4.44 ± 0.74 | 7.57 ± 1.19 | < 0.0001 |
| LH/FSH ratio | 0.87 ± 0.056 | 1.66 ± 0.24 | < 0.05 |
| PRL (ng/ml) b | 15.40 (1th 11.06, 3th 27.0) | 16.40 (1th 10.63, 3th 28.0) | > 0.05 |
| T3 (ng/ml) | 97.05 ± 2.17 | 76.06 ± 25.03 | > 0.05 |
| T4 (ng/ml) | 10.3 ± 1.53 | 8.04 ± 0.35 | = 0.05 |
| TSH (IU/L) | 2.01 ± 0.27 | 2.54 ± 0.32 | > 0.05 |
| Vitamin D (ng/ml) | 30.86 ± 5.40 | 32.61 ± 3.22 | > 0.05 |
AMH Anti Mullerian Hormone, BMI Body Mass Index; FBS Fasting Blood Sugar; FSH Follicle Stimulating Hormone; LH Luteinizing Hormone; PCOS Polycystic Ovary Syndrome; PRL Prolactin; T3 Triiodothyronine; T4 Thyroxine; TSH Thyroid Stimulating Hormone.
a: With the exception of prolactin, data are presented as the mean ± standard error of mean (SEM).
b: Prolactin was a non-normally distributed variable and data are presented as the median, first (1th) and third (3th) quartiles.
c: Statistically significant p values shown as bold.